HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

L Klareskog Selected Research

Antigens

5/2009Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles.
10/2001Skeletal muscle fibers express major histocompatibility complex class II antigens independently of inflammatory infiltrates in inflammatory myopathies.
10/2001A vegan diet free of gluten improves the signs and symptoms of rheumatoid arthritis: the effects on arthritis correlate with a reduction in antibodies to food antigens.
2/2001Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFalpha receptors.
1/2000Interferon-gamma production in response to in vitro stimulation with collagen type II in rheumatoid arthritis is associated with HLA-DRB1(*)0401 and HLA-DQ8.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


L Klareskog Research Topics

Disease

49Rheumatoid Arthritis
01/2018 - 01/2000
20Necrosis
01/2011 - 06/2000
12Arthritis (Polyarthritis)
01/2017 - 05/2000
8Inflammation (Inflammations)
03/2014 - 06/2000
6Experimental Arthritis
01/2017 - 01/2000
5Lymphoma (Lymphomas)
01/2018 - 10/2005
5Systemic Lupus Erythematosus (Libman-Sacks Disease)
03/2008 - 08/2000
5Rheumatic Diseases (Rheumatism)
11/2005 - 06/2000
4Neoplasms (Cancer)
08/2009 - 10/2005
2Pain (Aches)
01/2011 - 11/2005
2Infections
08/2009 - 12/2000
2Dermatomyositis (Dermatopolymyositis)
10/2001 - 05/2000
2Human Influenza (Influenza)
02/2001 - 01/2000
2Mixed Connective Tissue Disease (MCTD)
01/2001 - 05/2000
1Acquired Immunodeficiency Syndrome (AIDS)
01/2021
1Osteophyte
01/2017
1Osteoarthritis
01/2017
1Congenital heart block
06/2014
1Genetic Risk Score
03/2014
1Ankylosing Spondylitis
09/2006
1Giant Cell Arteritis (Horton Disease)
12/2005
1Polymyalgia Rheumatica (Rhizomelic Pseudopolyarthritis)
12/2005
1Skin Neoplasms (Skin Cancer)
10/2005
1Colorectal Neoplasms (Colorectal Cancer)
10/2005
1Melanoma (Melanoma, Malignant)
10/2005
1Body Weight (Weight, Body)
04/2004
1Nephritis
01/2004
1Lupus Nephritis
01/2004
1Atrophy
11/2002

Drug/Important Bio-Agent (IBA)

12Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
08/2009 - 06/2000
9Biological ProductsIBA
08/2011 - 06/2000
9Etanercept (Enbrel)FDA Link
03/2011 - 05/2002
8CytokinesIBA
03/2005 - 05/2000
7AntibodiesIBA
01/2018 - 01/2000
6AutoantibodiesIBA
01/2018 - 05/2000
6Anti-Citrullinated Protein AntibodiesIBA
01/2018 - 05/2009
6Antirheumatic Agents (DMARD)IBA
03/2011 - 03/2001
5Tumor Necrosis Factor InhibitorsIBA
01/2011 - 10/2005
5Methotrexate (Mexate)FDA LinkGeneric
06/2009 - 08/2005
5AntigensIBA
05/2009 - 01/2000
4Pharmaceutical PreparationsIBA
08/2009 - 05/2000
4Proteins (Proteins, Gene)FDA Link
09/2006 - 02/2001
4Interleukin-10 (Interleukin 10)IBA
01/2002 - 08/2000
3Biomarkers (Surrogate Marker)IBA
01/2018 - 03/2005
3cyclic citrullinated peptideIBA
01/2018 - 10/2008
3Collagen Type II (Type II Collagen)IBA
01/2017 - 01/2000
3Peptides (Polypeptides)IBA
03/2015 - 12/2005
3EpitopesIBA
05/2009 - 10/2008
3Rituximab (Mabthera)FDA Link
03/2008 - 01/2004
3TEMPOIBA
12/2007 - 08/2005
3Interleukin-1 Receptors (Interleukin 1 Receptor)IBA
11/2005 - 05/2000
3Infliximab (Remicade)FDA Link
09/2004 - 12/2003
2Immunoglobulin A (IgA)IBA
01/2018 - 04/2000
2Immunoglobulin G (IgG)IBA
01/2018 - 05/2000
2Immunoglobulin M (IgM)IBA
01/2018 - 03/2014
2Hyaluronic Acid (Hyaluronan)IBA
01/2017 - 09/2002
2HLA-DRB1 Chains (HLA DRB1)IBA
05/2009 - 02/2009
2Cyclophosphamide (Cytoxan)FDA LinkGeneric
03/2008 - 01/2004
2Prednisolone (Predate)FDA LinkGeneric
09/2007 - 01/2004
2Adrenal Cortex Hormones (Corticosteroids)IBA
12/2005 - 04/2004
2Fibrinogen (Factor I)FDA Link
04/2004 - 09/2002
2Cartilage Oligomeric Matrix ProteinIBA
04/2004 - 09/2002
2Interleukin-6 (Interleukin 6)IBA
10/2002 - 06/2000
2Interferon-gamma (Interferon, gamma)IBA
04/2001 - 01/2000
2Tuberculin (PPD)IBA
02/2001 - 01/2000
2AutoantigensIBA
02/2001 - 01/2000
2Interleukin-1alpha (Interleukin 1 alpha)IBA
11/2000 - 06/2000
1gamma-glutamyl 4-phenylene diamine mustardIBA
01/2021
1Cyclic PeptidesIBA
01/2017
1pristane (pristan)IBA
01/2017
1brassIBA
03/2014
1Rheumatoid FactorIBA
03/2014
1Serotonin ReceptorsIBA
03/2013
1C-Reactive ProteinIBA
01/2011
1golimumabFDA Link
06/2009
1HLA-DR Antigens (HLA-DR)IBA
10/2008
1Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA
07/2008
1LigandsIBA
07/2008
1QuinoxalinesIBA
04/2008
19- chloro- 2,3- dimethyl- 6- (N,N- dimetylamino- 2- oxoethyl)- 6H- indolo(2,3- b)quinoxalineIBA
04/2008
1GlucocorticoidsIBA
09/2007
1ORALIT (ORS)IBA
09/2006
1Anti-Idiotypic AntibodiesIBA
12/2005
1SteroidsIBA
12/2005
1amsonic acid (DAS)IBA
11/2005
1SmokeIBA
10/2005
1Adalimumab (Humira)FDA Link
09/2005
1Silicon Dioxide (Silica)FDA LinkGeneric
04/2005
1semapimodIBA
03/2005
1Anticardiolipin AntibodiesIBA
09/2004
1A-factor (Streptomyces)IBA
07/2004
1Prostaglandins EIBA
06/2004
1Prostaglandin-E SynthasesIBA
06/2004
1Betamethasone (Celestone)FDA Link
04/2004
1Monoclonal AntibodiesIBA
01/2004
1Genetic Markers (Genetic Marker)IBA
06/2003

Therapy/Procedure

11Therapeutics
08/2011 - 07/2000
2Aftercare (After-Treatment)
10/2005 - 02/2001
1Intra-Articular Injections
01/2017
1Subcutaneous Injections
06/2009